This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.
The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.
The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.
Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.
Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.
Specialty carve outs that move specialty drugs away from traditional prescription drug management to a pharmacy benefit administrator (PBA) or specialty administrator will continue and likely to provide cost savings.
What we need to overcome adherence challenges is a digitally enabled marketplace of options that can be personalized to the patient and the context of their specific condition, pharmacy preference and ability to pay.
The more pressing issue is that there is no mechanism in place to make this information easily digestible, personalized to each patient, and placed in context with competitors’ prices. Price transparency has come a long way over the past couple of years, with insurance companies and hospitals now required to publicly disclose their prices.
The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?
We can apply this approach in pharma by enhancing our patient journey maps and go beyond focusing on the key clinical engagement touch points (e.g., doctor visits, prescription pickups) and enriching our insights with the micro-moments surrounding these obvious events.
In 2023, prescription drug costs rose by 8.4%, a 31% increase from the prior year. If these dual forces converge, they have the power to bring about a transformative shift that can lower drug spend for millions of American patients. 2024 stands at a critical juncture in the battle against soaring pharmacy costs.
In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance.
Bryan Johnson Senior Director, Product Management, Compass Prescriber Veeva Systems Paving the Way to Faster Treatment Starts Bryan’s exposure to life sciences started at a young age, watching his father’s career at companies like Johnson & Johnson and emerging biopharmas. As rare diseases affect about 1 in 10 people in the U.S.,
The goal was simple: provide access and focused support to patients remotely while simultaneously relieving overtaxed healthcare facilities. Combined, DTx and DCTs improve patient recruitment, retention, and access, allowing researchers to pull from underserved communities, including rural populations.
Digital health company Happify has signed a partnership with another biopharma company, joining forces with Biogen on a toolkit to help people with multiple sclerosis manage their illness. ” The post Biogen and Happify partner on digital support for MS patients appeared first on. .
The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most.
Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.
Sumitomo and its subsidiary Sumitovant Biopharma initially offered $22.75 At the time, Myovant said Myfembree was the market leader in the oral GnRH category with a 51% share in new prescriptions for uterine fibroids that was keeping it ahead of main rival AbbVie/Neurocrine Biosciences’ Orilissa/Oriahnn (elagolix).
LHON mutation rate variability affects therapeutic efficacy Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 The Clarivate U.S.
To realize true, sustainable savings in total cost of care, the healthcare system needs to reconsider the support — or lack of support — it provides throughout patients’ medication experiences and the snowball effect that creates on a lifetime of healthcare costs.
Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.
Learnings from bringing clinical trial management in-house, and how to modernize your approach to patient-first trials with advanced data science, real-world data and other patient intelligence. Clearly, making sure that we’ve got the right patients and principal investigators is still a challenge.
As the COVID-19 pandemic continues to evolve, we are seeing substantial shifts in the way patients access healthcare and how providers deliver care. 2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. hours seeing patients.
Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time.
biologics market and reduce prescription drug costs. This strategy is reacting to the cost challenges patients face and is an “affordable solution for patients who are uninsured, underinsured, or recently separated from Medicaid coverage,” said Coherus chief business officer Chris Slavinsky in a statement.
Any reduced availability of medicines has a significant impact on patient care. As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. The CMO solution.
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. With 27.5%
Demerging Haleon has allowed GSK to focus on higher-margin prescription medicines and vaccines, as well as provide cash for investment in its biopharma pipeline. Total revenues came in at £6.9 billion ($8.3 GSK has already made moves in this direction this year with deals to buy cancer specialist Sierra Oncology for $1.9
Mackay has been CFO at the UK big pharma since the beginning of 2019, and is departing the company shortly after the spin-out of consumer health business Haleon in order to focus on prescription drugs and vaccines. “I am looking forward to working together to deliver progress for patients, shareholders, and our people.”
Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices.
Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. The medication referenced in this case study is a prescription medication used, along with diet and exercise, to lower blood sugar in adults with type 2 diabetes.
Historically, the pharmaceutical industry is economically sturdy, but three things are not: patients’ household budgets, marketing department budgets, and small-company budgets. Biopharma valuations are down, especially for public and earlier-stage companies. Implications of economic volatility abound: Patients: Market access gaps.
Historically, the pharmaceutical industry is economically sturdy, but three things are not: patients’ household budgets, marketing department budgets, and small-company budgets. Biopharma valuations are down, especially for public and earlier-stage companies. Implications of economic volatility abound: Patients: Market access gaps.
Half of the psychiatrists surveyed reported having prescribed or recommended DTx to patients within the three studied indications, while the remainder indicated they expect or are open to prescribing them. Nearly two-thirds of MCOs developed a comprehensive coverage policy for DTx, while the rest are working on or intend to develop one.
Mainland China has streamlined regulatory protocols for testing and approving prescription drugs in recent years, making dozens of urgently needed treatments, from domestic and international manufacturers alike, available to patients in the process.
Which data points provide the most actionable insights to inform future social media, marketing, and patient education efforts? Lastly, with the pending cookie deprecation, marketers must have identity solutions ready to deploy in lieu of 1P matched HCP or patient data. Plan your tactics to address any challenges accordingly.
Lack of information based on clinical data can mean providers and patients decide against treating underlying conditions, “which in some cases may result in more harm” to the parent and the fetus than if they had received treatment.
The biopharma industry is sweating the long-term implications and warning that it could mean less lifesaving drugs make it to patients going forward. The law was top-of-mind at this summer’s ASCO and BIO meetings, tentpole events in the biopharma conference calendar.
Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.
Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. The waiver allows patients to be seen across geographic lines and in any setting. As of Aug.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content